Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ViP: Rofecoxib for Prostate Cancer Prevention
NCT00060476Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2003
- Primary completion
- Dec 2004
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of rofecoxib in prostate cancer (PCa), sponsored by Merck & Co.. Started Jan 2003; status: completed.
02
Drugs
rofecoxib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00060476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00060476.